ZYBERNO
Stock Report
Updated Aug 31, 2026

ONKURE THERAPEUTICS, INC. (OKUR)

Healthcare • NASDAQ

$3.79

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
28.0/100
POOR BUSINESS
ONKURE THERAPEUTICS, INC. (OKUR) scores 28/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-49.0%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.01x)
Operating Margin (Operational Efficiency):CRITICAL (-1,804.8%)
Return on Capital (Capital Efficiency):CRITICAL (-713.5%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

ONKURE THERAPEUTICS, INC. (OKUR) stock report — Zyberno Score 28/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, OKUR generated -$50.79M in Owner Earnings. Capital was deployed as follows: $33.00K invested in capital expenditures. Reinvestment rate: 0.9%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:3.79
Market Cap:$189.00M

Valuation Multiples (3)

P/B Ratio:1.10x
P/S Ratio:54.90x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$23.43M

Price Action & Momentum (3)

Momentum Percentile:91 / 100
% of 52-Week High:70.4%
B. Profitability Assessment

Return Metrics (5)

ROA:-45.8%
Reinvestment Rate:0.9%
Fundamental Growth Rate (g):-6.1%

Margin Analysis (3)

Operating Margin Ttm:-1,804.8%
Net Margin Ttm:-1,705.1%
Ebitda Margin:-1,792.2%

TTM Performance (2)

Operating Margin Ttm:-1,804.8%
Net Margin Ttm:-1,705.1%

Yield Metrics (2)

Earnings Yield:-$89.49
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:71.8%
Latest Earnings Filed:2026-08-04

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):-6.2%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:26.75x
Quick Ratio:26.75x
Cash Ratio:25.06x

Leverage Analysis (3)

Debt To Equity Ttm:0.01x
Debt-to-Equity Ratio:0.01x
Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-16.80x
Times Interest Earned:-16.80

Capital Structure (4)

Working Capital:171,034,000.00
Cash And Cash Equivalents:166,502,000.00
Long Term Debt:$590.00K
Net Debt:-$165.58M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $3.44M
Linear Growth: -6.2%
📊 Click to view full OKUR Revenue analysis & methodology →
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$62.14M

Bottom Line Performance (3)

-$58.71M
Income Before Tax:$0.00
Ebitda Ttm:-61,707,000.00

Operating Expenses (5)

Operating Expenses:62,140,000.00
R And D Expense:46,953,000.00
Sga Expense:15,187,000.00
Income Tax Expense:$0.00
Interest Expense:3,747,000.00

Expense Ratios (3)

R And D To Revenue Percentage:3,023.4%
Sga To Revenue Percentage:977.9%
Ebitda Margin:-1,792.2%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$179.35M
Current Assets:$177.68M
Ppe Net:2,082,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:7,245,000.00
Current Liabilities:6,643,000.00
Long Term Debt:$590.00K
Short Term Debt:$336.00K

Equity & Capital (3)

Equity:$172.11M
Retained Earnings:-$244.74M
Common Stock:210,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:1,999,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:3,049,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$50.76M-$50.79M

Investment Activities (2)

Investing Cash Flow:-$5.00K
Capital Expenditures Ttm:33,000.00

Financing Activities (3)

Financing Cash Flow:$146.00M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:433,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-3.49
-$3.49
Earnings Per Share Ttm:-$1.18

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.07
Operating Cash Flow Per Share:-$1.04

Book Value & Capital (2)

Book Value Per Share:$3.45
Cash Per Share:3.34

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.03x
Working Capital Turnover Ttm:0.02x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:211.92
Cash Conversion Cycle:-2,209.92
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:40.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$50.79M

Damodaran Growth Analysis (2)

Reinvestment Rate:0.9%
Fundamental Growth Rate (g):-6.1%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):-6.2%

Other Growth Rates (1)

Book Value Growth Rate (Linear):-3.8%
C. Company Profile & Context

Corporate Information (6)

Symbol:OKUR
Company Name:ONKURE THERAPEUTICS, INC.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:low
Volume Category:N/A

Share Structure (3)

Shares Outstanding:49.87M
Shares Outstanding Basic:49.87M
Shares Outstanding Diluted:49.87M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-31 10:52:47 UTC
Data Timestamp:2026-08-19T02:45:06.267903
Scroll to Top